Security
Ultragenyx Pharmaceutical Inc. Common Stock · RARE
RARENASDAQCommon stockCurrentCIK 1515673Updated Oct 31, 2026
RARE price & chart
Loading TradingView…
NASDAQ:RARE on TradingView ↗About the company
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE ↗
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm ↗
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE ↗
Recent filings
Other Events
Items 8.01
Entry into a Material Definitive Agreement
Items 1.01
Entry into a Material Definitive Agreement
Items 1.01
Other Events
Items 8.01
144 filing
Show 5 more recent filings
Other Events
Items 8.01
Other Events
Items 8.01
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,190,445,000Source | 1,538,363,000Source | 1,264,000,000Source | 1,306,265,000Source | 1,618,437,000Source | 1,296,000,000Source | 1,311,927,000Source | 1,307,080,000Source | 1,532,000,000Source | 1,503,456,000Source | 1,491,013,000Source | 1,545,444,000Source |
| Property, Plant and Equipment, NetUSD | 249,961,000Source | 272,448,000Source | 235,000,000Source | 255,763,000Source | 278,707,000Source | 239,000,000Source | 260,906,000Source | 285,111,000Source | 244,000,000Source | 265,929,000Source | 290,566,000Source | 259,726,000Source |
| GoodwillUSD | 44,406,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,406,000Source | 44,406,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 172,943,000Source | 164,942,000Source | 172,000,000Source | 174,733,000Source | 166,243,000Source | 174,000,000Source | 176,524,000Source | 165,045,000Source | 176,000,000Source | 178,314,000Source | 166,271,000Source | 160,105,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 202,510,000Source | 150,619,000Source | 125,000,000Source | 176,000,000Source | 480,693,000Source | 175,000,000Source | 127,000,000Source | 112,250,000Source | 421,000,000Source | 173,729,000Source | 213,584,000Source | 132,944,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 112,543,000Source | 93,301,000Source | 200,000,000Source | 124,464,000Source | 105,982,000Source | 121,000,000Source | 98,839,000Source | 100,253,000Source | 158,000,000Source | 121,801,000Source | 73,390,000Source | 40,445,000Source |
| Inventory, NetUSD | 52,200,000Source | 43,334,000Source | 59,000,000Source | 46,498,000Source | 40,137,000Source | 55,000,000Source | 46,031,000Source | 35,907,000Source | 52,000,000Source | 45,007,000Source | 33,969,000Source | 26,766,000Source |
| Assets, CurrentUSD | 643,206,000Source | 799,608,000Source | 606,000,000Source | 719,788,000Source | 964,640,000Source | 657,000,000Source | 699,155,000Source | 595,967,000Source | 951,000,000Source | 817,123,000Source | 732,184,000Source | 883,899,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 53,215,000Source | — | 55,000,000Source | 61,241,000Source | — | 68,000,000Source | 59,845,000Source | — | 61,000,000Source | 40,290,000Source | — | 68,926,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 23,000,000Source | 25,500,000Source | 23,900,000Source | 25,961,000Source |
| Other Assets, NoncurrentUSD | 57,862,000Source | 53,873,000Source | 63,000,000Source | 60,121,000Source | 53,772,000Source | 61,000,000Source | 62,373,000Source | 59,970,000Source | 60,000,000Source | 62,680,000Source | 57,685,000Source | 16,846,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,174,286,000Source | 1,184,536,000Source | 1,548,000,000Source | 1,147,979,000Source | 1,186,019,000Source | 1,525,000,000Source | 1,160,681,000Source | 1,166,816,000Source | 1,605,000,000Source | 1,241,159,000Source | 1,215,599,000Source | 1,192,950,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 96,000Source | 92,000Source | 0Source | 96,000Source | 92,000Source | 0Source | 94,000Source | 83,000Source | 0Source | 92,000Source | 82,000Source | 70,000Source |
| Additional Paid in CapitalUSD | 4,411,531,000Source | 4,169,298,000Source | 4,518,000,000Source | 4,374,333,000Source | 4,123,364,000Source | 4,481,000,000Source | 4,252,417,000Source | 3,698,957,000Source | 4,451,000,000Source | 4,212,692,000Source | 3,662,346,000Source | 3,140,019,000Source |
| Retained Earnings (Accumulated Deficit)USD | -4,403,288,000Source | -3,823,459,000Source | -4,809,000,000Source | -4,222,875,000Source | -3,689,943,000Source | -4,717,000,000Source | -4,107,924,000Source | -3,558,345,000Source | -4,532,000,000Source | -3,956,844,000Source | -3,387,661,000Source | -2,781,022,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 820,000Source | 896,000Source | 0Source | -268,000Source | -1,095,000Source | 0Source | -341,000Source | -431,000Source | 1,000,000Source | -643,000Source | 647,000Source | -6,573,000Source |
| Stockholders' Equity Attributable to ParentUSD | 9,159,000Source | 346,827,000Source | -291,000,000Source | 151,000,000Source | 432,418,000Source | -236,000,000Source | 144,000,000Source | 140,264,000Source | -80,000,000Source | 255,297,000Source | 275,414,000Source | 352,494,000Source |
| Liabilities and EquityUSD | 1,190,445,000Source | 1,538,363,000Source | 1,264,000,000Source | 1,306,265,000Source | 1,618,437,000Source | 1,296,000,000Source | 1,311,927,000Source | 1,307,080,000Source | 1,532,000,000Source | 1,503,456,000Source | 1,491,013,000Source | 1,545,444,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 340,022,000Source | 285,008,000Source | 351,000,000Source | 293,244,000Source | 272,866,000Source | 325,000,000Source | 291,668,000Source | 245,575,000Source | 384,000,000Source | 344,153,000Source | 280,437,000Source | 261,210,000Source |
| Operating Lease, Liability, CurrentUSD | 12,142,000Source | — | — | 11,766,000Source | — | — | 10,487,000Source | — | 12,000,000Source | 10,297,000Source | 12,595,000Source | 11,596,000Source |
| Accounts Payable, CurrentUSD | 40,573,000Source | 35,990,000Source | 39,000,000Source | 34,242,000Source | 59,807,000Source | 42,000,000Source | 47,450,000Source | 40,972,000Source | 31,000,000Source | 38,756,000Source | 42,114,000Source | 43,274,000Source |
| Operating Lease, Liability, NoncurrentUSD | 21,691,000Source | — | — | 24,531,000Source | — | — | 27,786,000Source | — | 24,000,000Source | 30,042,000Source | 30,574,000Source | 19,814,000Source |
| Deferred Income Tax Liabilities, NetUSD | 30,058,000Source | 30,058,000Source | 30,000,000Source | 30,058,000Source | 30,058,000Source | 30,000,000Source | 30,058,000Source | 30,058,000Source | 30,000,000Source | 30,058,000Source | 30,058,000Source | 31,667,000Source |
| Other Liabilities, NoncurrentUSD | 18,780,000Source | 16,127,000Source | 41,000,000Source | 17,398,000Source | 15,197,000Source | 42,000,000Source | 17,123,000Source | 14,479,000Source | 20,000,000Source | 17,082,000Source | 12,205,000Source | 4,820,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 220,526,000Source | 185,028,000Source | 221,000,000Source | 180,792,000Source | 154,421,000Source | 194,000,000Source | 173,007,000Source | 149,133,000Source | 265,000,000Source | 240,973,000Source | 196,486,000Source | 204,678,000Source |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 588,000Source | 3,073,000Source | -1,000,000Source | 575,000Source | -399,000Source | -1,000,000Source | 917,000Source | 46,000Source | 0Source | 1,007,000Source | 1,253,000Source | -5,728,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 29,000,000Source | 28,686,000Source | 30,058,000Source | 31,667,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 8,000,000Source | 9,000,000Source | 35,000,000Source | 35,543,000Source | 26,006,000Source | 18,220,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -19,000,000Source | -10,000,000Source | 31,000,000Source | 33,598,000Source | 22,778,000Source | 12,068,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 4,000,000Source | 1,000,000Source | 6,000,000Source | 11,207,000Source | 6,930,000Source | 9,701,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 1,372,000Source | 1,765,000Source | -1,640,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -197,000,000Source | -166,000,000Source | -466,000,000Source | -414,188,000Source | -474,806,000Source | -380,465,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 75,025,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -49,000,000Source | 120,000,000Source | 236,000,000Source | -17,768,000Source | 168,000,000Source | -291,652,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 1,000,000Source | 1,000,000Source | 2,436,000Source | 5,048,000Source | 844,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,000,000Source | 1,000,000Source | 6,000,000Source | 7,491,000Source | 44,267,000Source | 116,123,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 157,000Source | 478,000,000Source | 399,241,000Source | 388,142,000Source | 501,208,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | -28,000Source | -555,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -247,000,000Source | -45,000,000Source | 252,000,000Source | -35,240,000Source | 81,798,000Source | -171,984,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 4,000,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 37,010,000Source | 41,569,000Source | 34,000,000Source | 39,000,000Source | 30,000Source | 40,000Source | 153,000,000Source | 158,056,000Source | 135,213,000Source | 130,368,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 678,000Source | 678,000Source | — | -9,000Source | — | -157,000Source | — | -1,115,000Source | 397,000Source | -19,299,000Source |
| GoodwillUSD | — | — | 44,406,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,000,000Source | 44,406,000Source | 44,406,000Source | 44,406,000Source |
| Income Tax Expense (Benefit)USD | — | — | 873,000Source | 303,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source | 4,000,000Source | 1,597,000Source | -1,825,000Source | 5,696,000Source |
| Investment Income, InterestUSD | — | — | 5,863,000Source | 10,731,000Source | 5,000,000Source | 6,000,000Source | 6,000,000Source | 7,000,000Source | 25,000,000Source | 36,506,000Source | 26,688,000Source | 11,074,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -180,413,000Source | -133,516,000Source | -92,000,000Source | -115,000,000Source | -185,000,000Source | -151,000,000Source | -575,000,000Source | -569,183,000Source | -606,639,000Source | -707,421,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,043,000Source | 3,077,000Source | 1,000,000Source | 2,000,000Source | — | 837,000Source | 1,000,000Source | -3,963,000Source | -337,000Source | -1,566,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 88,000,000Source | 137,000,000Source | 444,000,000Source | 410,025,000Source | 695,525,000Source | 450,706,000Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | 0Source | 7,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 5,736,000Source | 2,700,000Source | 6,200,000Source |
| Restructuring Costs | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 159,933,000Source | 139,494,000Source | 214,000,000Source | 167,000,000Source | 136,000,000Source | 139,000,000Source | 673,000,000Source | 560,230,000Source | 434,249,000Source | 363,329,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 86,620,000Source | 80,351,000Source | 88,000,000Source | 87,000,000Source | 88,000,000Source | 87,000,000Source | 349,000,000Source | 321,610,000Source | 309,799,000Source | 278,139,000Source |
| Operating Income (Loss)USD | — | — | -170,890,000Source | -131,987,000Source | -75,000,000Source | -108,000,000Source | -169,000,000Source | -143,000,000Source | -535,000,000Source | -535,973,000Source | -569,208,000Source | -648,919,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,043,000Source | 3,077,000Source | 1,000,000Source | 2,000,000Source | — | 837,000Source | 1,000,000Source | -3,963,000Source | -337,000Source | -1,566,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -179,540,000Source | -133,213,000Source | -91,000,000Source | -114,000,000Source | -184,000,000Source | -150,000,000Source | -571,000,000Source | -567,586,000Source | -608,464,000Source | -701,725,000Source |
| Income Tax Expense (Benefit)USD | — | — | 873,000Source | 303,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source | 4,000,000Source | 1,597,000Source | -1,825,000Source | 5,696,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -180,413,000Source | -133,516,000Source | -92,000,000Source | -115,000,000Source | -185,000,000Source | -151,000,000Source | -575,000,000Source | -569,183,000Source | -606,639,000Source | -707,421,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.81Source | -1.4Source | -0.9Source | -1.17Source | -1.84Source | -1.57Source | -5.83Source | -6.29Source | -8.25Source | -10.12Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.81Source | -1.4Source | -0.9Source | -1.17Source | -1.84Source | -1.57Source | -5.83Source | -6.29Source | -8.25Source | -10.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 99,771,297Source | 95,493,996Source | 101,900,000Source | 98,500,000Source | 100,600,000Source | 96,300,000Source | 98,600,000Source | 90,538,118Source | 73,543,862Source | 69,914,225Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 99,771,297Source | 95,493,996Source | 101,900,000Source | 98,500,000Source | 100,600,000Source | 96,300,000Source | 98,600,000Source | 90,538,118Source | 73,543,862Source | 69,914,225Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 4,000,000Source | 2,969,000Source | -60,000Source | 7,336,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -565,000,000Source | -564,072,000Source | -608,166,000Source | -703,411,000Source |
| Investment Income, InterestUSD | — | — | 5,863,000Source | 10,731,000Source | 5,000,000Source | 6,000,000Source | 6,000,000Source | 7,000,000Source | 25,000,000Source | 36,506,000Source | 26,688,000Source | 11,074,000Source |
| Research and Development ExpenseUSD | — | — | 216,212,000Source | 170,109,000Source | 167,000,000Source | 165,000,000Source | 187,000,000Source | 166,000,000Source | 750,000,000Source | 697,865,000Source | 648,449,000Source | 705,789,000Source |
| Restructuring Costs | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
Filing attachments
rare-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com MediaJess Rowlands media@ultragenyx.com Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update Second quarter total revenue of $214 million, Crysvita® revenue of $156 million and Dojolvi® revenue of $27 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A e…
Read attachment ↗rare-ex4_4.htm · S-8 · 2026-06-12
Exhibit 4.4 Ultragenyx Pharmaceutical Inc. Third Amended and Restated 2023 Incentive Plan 1. DEFINED TERMS Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. PURPOSE The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock-based and other incentive Awards. The Plan was originally approved by the Board on April 20, 2023 effecti…
Read attachment ↗rare-ex4_9.htm · S-8 · 2026-06-12
Exhibit 4.9 FOURTH AMENDMENT TO THE Ultragenyx Pharmaceutical Inc. Employment Inducement Plan WHEREAS, Ultragenyx Pharmaceutical Inc., a Delaware corporation (the “Company”) maintains the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan, as amended (the “Plan”); and WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee of the Board of Directors of the Company may amend the Plan at any time and for any purpose as permitted by law, including to increase the maximum n…
Read attachment ↗rare-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com MediaJess Rowlands media@ultragenyx.com Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expe…
Read attachment ↗rare-ex99_1.htm · 8-K · 2026-02-12
Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com MediaJess Rowlands media@ultragenyx.com Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update 2025 total revenue of $673 million, Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce a…
Read attachment ↗rare-ex99_1.htm · 8-K · 2026-01-12
EX-99.1 2 rare-ex99_1.htm EX-99.1 EX-99.1 Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif. - January 12, …
Read attachment ↗